Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||PF-04518600 + Rituximab + Utomilumab|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|PF-04518600||PF-8600|PF04518600||OX40 Antibody 10||PF-04518600 is an activating monoclonal antibody to TNFRSF4 (OX40, CD134), which mimics the binding of the ligand, TNFSF4 (OX40L, CD252), to stimulate proliferation of T-cells and enhance an anti-tumor response (Journal of Clinical Oncology 34, no. 15_suppl (May 20 2016) 3079-3079).|
|Rituximab||Rituxan||IDEC-C2B8|MabThera||CD20 Antibody 10||Rituxan (rituximab) is a chimeric mononclonal antibody that binds to CD20 on B-cells, resulting in induction of complement-dependent and antibody-dependent cytotoxicity, and potentially leading to decreased B-cell tumor growth (PMID: 28983798). Rituxan (rituximab) is FDA approved for use as monotherapy or in combination with chemotherapy in CD20-positive B-cell non-Hodgkin lymphoma, and in combination with fludarabine and cyclophosphamide in CD20-positive chronic lymphocytic leukemia (FDA.gov).|
|Utomilumab||PF-05082566|PF05082566||Utomilumab (PF-05082566) is an activating monoclonal antibody that targets and antagonizes CD137 (4-1BB), potentially resulting in increased immune response against tumor cells (PMID: 27369047, PMID: 32144134).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|
|NCT03636503||Phase I||Avelumab + Rituximab + Utomilumab Avelumab + PF-04518600 + Rituximab PF-04518600 + Rituximab + Utomilumab||RITUXIMAB + IMMUNOTHERAPY IN FOLLICULAR LYMPHOMA||Recruiting|